Controversies and new approaches to treatment of Langerhans cell histiocytosis

Hematology/Oncology Clinics of North America

Volumn 12, Issue 2, 1998, Pages 339-357

  Arceci, R J ^a   Brenner, M K ^a   Pritchard, J ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 2; MERCAPTOPURINE; METHOTREXATE; METHOXSALEN; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; VINDESINE;

BONE MARROW TRANSPLANTATION; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG EFFICACY; GENE TRANSFER; HISTIOCYTOSIS X; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; PUVA; REVIEW; TREATMENT OUTCOME;

EID: 0031900577     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70514-1     Document Type: Article

References (223)

1. A. Akesson A. Scheja A. Lundin Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide Arthritis Rheum 37 1994 729 735
2. J. Albanell A. Salud J. Bellmunt [Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult] Medicina Clinica 94 1990 184 186
3. Anonymous A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group Arch Dis Child 75 1996 17 24
4. R. Arceci Histiocytoses and disorders of the reticuloendothelial system R.I. Handin S.E. Lux T.P. Stossel Blood: Principles and Practice of Hematology. 1995 JB Lippincott Philadelphia 915 946
5. R. Arceci Tumor cell survival and resistance to therapy Curr Opin Hematol 3 1996 279 287
6. R.J. Arceci Clinical Significance of the MDR1 P-Glycoprotein Blood 81 1993 2215 2222
7. R.J. Arceci Treatment options—commentary Br J Cancer 23 suppl 1994 58 60
8. F. Arenzana-Seisdedos S. Barbey J.L. Virelizier Histiocytosis X. Purified (T6+) cells from bone granuloma produce interleukin 1 and prostaglandin E2 in culture J Clin Invest 77 1986 326 329
9. M. Arico R. Colella V. Conter Cyclosporine therapy for refractory Langerhans cell histiocytosis Med Pediatr Oncol 25 1995 12 16
10. C.M. Baecher-Allan R.K. Barth PCR analysis of cytokine induction profiles associated with mouse strain variation in susceptibility to pulmonary fibrosis Regional Immunology 5 1993 207 217
11. P. Baliga K.D. Chavin L. Qin CTLA4-Ig prolongs allograft survival while suppressing cell-mediated immunity Transplantation 58 1994 1082 1090
12. G. Bandara G.M. Mueller J. Galea-Lauri Intraarticular expression of biologically active interleukin-1-receptor-antagonist protein by ex vivo gene transfer Proc Natl Acad Sci USA 90 1993 10764 10768
13. J.C. Becker J.D. Pancook S.D. Gillies T cell–mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy J Exp Med 183 1996 2361 2366
14. A. Begleiter H. Wang L. Verburg In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia Leukemia 10 1996 1959 1965
15. J. Bellmunt J. Albanell A. Salud Interferon and disseminated Langerhans cell histiocytosis Med Pediatr Oncol 20 1992 336 337
16. M.C. Benyunes C. Higuchi A. York Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: A feasibility trial Bone Marrow Transplant 16 1995 283 288
17. Y. Bertrand Treatment of severe forms of Langerhans cell histiocytosis Pediatrie 48 1993 770 774
18. D.L. Betcher N. Burnham 2-Chlorodeoxyadenosine J Pediatr Oncol Nurs 9 1992 192 193
19. D.C. Betticher M.F. Fey A. von Rohr High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias Ann Oncol 5 1994 57 64
20. E. Beutler D.A. Carson 2-Chlorodeoxyadenosine: Hairy cell leukemia takes a surprising turn Blood Cells 19 1993 559 568
21. S. Bhatia N.K. Ramsay M. Steinbuch Malignant neoplasms following bone marrow transplantation Blood 87 1996 3633 3639
22. D.C. Birnbaum D. Shields B. Lippe Idiopathic central diabetes insipidus followed by progressive spastic cerebral ataxia. Report of four cases Arch Neurol 46 1989 1001 1003
23. B.R. Blazar P.A. Taylor P.S. Linsley In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice Blood 83 1994 3815 3825
24. O. Bletry T. Papo Interferons. Interferons alpha and gamma: Indications in systemic diseases Ann Med Interne (Paris) 144 1993 557 562
25. J.A. Bluestone New perspectives of CD28-B7–mediated T cell costimulation Immunity 2 1995 555 559
26. P.L. Bockenstedt J.T. Santinga S.F. Bolling Alpha-interferon treatment for idiopathic hypereosinophilic syndrome Am J Hematol 45 1994 248 251
27. P. Borst Genetic mechanisms of drug resistance. A review Acta Oncol 30 1991 87 105
28. C. Bradley J. Pitts The use of genetic marking to assess the interaction of sensitive and multidrug-resistant cells in mixed culture Br J Cancer 70 1994 795 798
29. M.K. Brenner The contribution of marker gene studies to hemopoietic stem cell therapies Stem Cells 13 1995 453 461
30. M.K. Brenner Genetic marking and manipulation of hematopoietic progenitor cells using retroviral vectors Immunomethods 5 1994 204 210
31. M.K. Brenner D.R. Rill R.C. Moen Gene-marking to trace origin of relapse after autologous bone-marrow transplantation Lancet 341 1993 85 86
32. V. Broadbent J. Pritchard Diabetes insipidus associated with Langerhans cell histiocytosis: Is it reversible? Med Pediatr Oncol 28 1997 289 293
33. V. Broadbent J. Pritchard E. Yeomans Etoposide (VP16) in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X) Med Pediatr Oncol 17 1989 97 100
34. S.A. Brod G.D. Marshall Jr E.M. Henninger Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis Neurology 46 1996 1633 1638
35. D.J. Burn J.D. Watson M. Roddie Langerhans' cell histiocytosis and the nervous system J Neurol 239 1992 345 350
36. D.M. Butler R.N. Maini M. Feldmann Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist European Cytokine Network 6 1995 225 230
37. L. Campos D. Guyotat E. Archimbaud Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis Blood 79 1992 473 476
38. J.R. Cassady Current role of radiation therapy in the management of histiocytosis-X Hematol Oncol Clin North Am 1 1987 123 129
39. S. Castaigne 2-Chlorodeoxyadenosine in haematological malignancies Nouv Rev Fr Hematol 35 1993 13 14
40. M.A. Castello A. Clerico A. Jenkner A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors Pediatr Hematol Oncol 7 1990 129 135
41. A. Ceci M. de Terlizzi R. Colella Etoposide in recurrent childhood Langerhans' cell histiocytosis: An Italian cooperative study Cancer 62 1988 2528 2531
42. A. Ceci M. de Terlizzi M.G. Toma Heterogeneity of immunological patterns in Langerhans histiocytosis and response to crude calf thymic extract in 11 patients Med Pediatr Oncol 16 1988 111 115
43. H.S. Chan G. DeBoer G. Haddad Multidrug resistance in pediatric malignancies Hematol Oncol Clin North Am 9 1995 275 318
44. T. Chu R. Jaffe The normal Langerhans cell and the LCH cell Br J Cancer 23 suppl 1994 4 10
45. W. Concepcion C.O. Esquivel A. Terry Liver transplantation in Langerhans' cell histiocytosis (histiocytosis X) Semin Oncol 18 1991 24 28
46. V. Conter A. Reciputo C. Arrigo Bone marrow transplantation for refractory Langerhans' cell histiocytosis Haematologica 81 1996 468 471
47. S.M. Davies N.K. Ramsay R.J. Haake Comparison of engraftment in recipients of matched sibling of unrelated donor marrow allografts Bone Marrow Transplant 13 1994 51 57
48. J.H. de Graaf G.P. Mannes R.Y. Tamminga The role of cytokines in the pathogenesis of pulmonary Langerhans' cell histiocytosis Adv Exp Med Biol 378 1995 535 537
49. N. de Wind M. Dekker A. Berns Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer Cell 82 1995 321 330
50. L.P. Dehner Allogeneic bone marrow transplantation in a patient with chemotherapy resistant progressive histiocytosis X [letter] N Engl J Med 317 1987 773
51. D. Dilloo K. Bacon W. Holden Combined chemokine and cytokine gene transfer enhances antitumor immunity Nature Med 2 1996 1090 1095
52. M.A. Dimopoulos H. Kantarjian E. Estey Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine Ann Intern Med 118 1993 195 198
53. M.A. Dimopoulos H. Kantarjian D. Weber Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine J Clin Oncol 12 1994 2694 2698
54. C.A. Dinarello Interleukin-1 and interleukin-1 receptor antagonist Nutrition 11 1995 492 494
55. T. Duell M.T. van Lint P. Ljungman Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation Ann Intern Med 126 1997 184 192
56. C.E. Dunbar A.W. Nienhuis F.M. Stewart Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia, or metastatic breast cancer Human Gene Therapy 4 1993 205 222
57. D.B. Dunger V. Broadbent E. Yeoman The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis N Engl J Med 321 1989 1157 1162
58. R.M. Egeler G.J. D'Angio Langerhans cell histiocytosis J Pediatr 127 1995 1 11
59. R.M. Egeler J. de Kraker P.A. Voute Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: Experience at a single institution Med Pediatr Oncol 21 1993 265 270
60. R.M. Egeler J.P. Neglia D.M. Puccetti Association of Langerhans cell histiocytosis with malignant neoplasms Cancer 71 1993 865 873
61. A.A. El-Ghorr M. Norval A monoclonal antibody to cis-urocanic acid prevents the ultraviolet-induced changes in Langerhans cells and delayed hypersensitivity responses in mice, although not preventing dendritic cell accumulation in lymph nodes draining the site of irradiation and contact hypersensitivity responses J Invest Dermatol 105 1995 264 268
62. A.A. El-Ghorr F. Pierik M. Norval Comparative potency of different UV sources in reducing the density and antigen-presenting capacity of Langerhans cells in C3H mice Photochemistry & Photobiology 60 1994 256 261
63. el-Sayed S. T.B. Brewin Histiocytosis X: Does radiotherapy still have a role Clinical Oncology (Royal College of Radiologists) 4 1992 27 31
64. A.G. Eliopoulos D.J. Kerr J. Herod The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2 Oncogene 11 1995 1217 1228
65. J.F. Emile S. Fraitag P. Andry Expression of GM-CSF receptor by Langerhans' cell histiocytosis cells Virchows Arch 427 1995 125 129
66. E.H. Estey R. Kurzrock H.M. Kantarjian Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA) Blood 79 1992 882 887
67. B.E. Favara Langerhans' cell histiocytosis pathobiology and pathogenesis Semin Oncol 18 1991 3 7
68. B.E. Favara R. Jaffe The histopathology of Langerhans cell histiocytosis Br J Cancer 23 suppl 1994 S17 S23
69. E.R. Fearon D.M. Pardoe T. Itaya Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Cell 60 1990 397 403
70. D.E. Fisher Apoptosis in cancer therapy: Crossing the threshold Cell 78 1994 539 542
71. R. Foa G. Meloni A. Guarini Has IL2 a role in the management of minimal residual disease for acute leukemia? Leukemia 6 1992 92 104
72. T. Forssman J. Fluhr D. Djawari Treatment of Langerhans-cell histiocytosis by oral cyclosporin A and topical nitrogen mustard Ann Dermatol Venereol 121 1994 734
73. H.D. Foss H. Herbst I. Araujo Monokine expression in Langerhans' cell histiocytosis and sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) J Pathol 179 1996 60 65
74. J.D. Frost S.R. Wiersma Progressive Langerhans cell histiocytosis in an infant with Klinefelter syndrome successfully treated with allogeneic bone marrow transplantation J Pediatr Hematol Oncol 18 1996 396 400
75. H. Gadner A. Heitger N. Grois Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group Med Pediatr Oncol 23 1994 72 80
76. H. Gadner A. Heitger J. Ritter Langerhans cell histiocytosis in childhood—results of the DAL-HX 83 study Klinische Padiatrie 199 1987 173 182
77. T.F. Gajewski F. Fallarino C. Uyttenhove Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7-2 for active tumor immunization J Immunol 156 1996 2909 2917
78. H. Goldberg-Stern R. Weitz R. Zaizov Progressive spinocerebellar degeneration “plus” associated with Langerhans cell histiocytosis: A new paraneoplastic syndrome? J Neurol Neurosurg Psychiatry 58 1995 180 183
79. L.J. Goldstein Clinical reversal of drug resistance Curr Probl Cancer 19 1995 65 124
80. R. Gramatovici G.J. D'Angio Radiation therapy in soft-tissue lesions in histiocytosis X (Langerhans' cell histiocytosis) Med Pediatr Oncol 16 1988 259 262
81. J.S. Greenberger J.R. Cassady N. Jaffe Radiation therapy in patients with histiocytosis: Management of diabetes insipidus and bone lesions Int J Radiat Oncol Biol Phys 5 1979 1749 1755
82. J.S. Greenberger A.C. Crocker G. Vawter Results of treatment of 127 patients with systemic histiocytosis (Letterer-Siwe syndrome, Schuller-Christian syndrome and multifocal eosinophilic granuloma) Medicine 60 1981 311 338
83. H.T. Greinix R. Storb J.E. Sanders Marrow transplantation for treatment of multisystem progressive Langerhans cell histiocytosis Bone Marrow Transplant 10 1992 39 44
84. N. Grois A.J. Barkovich W. Rosenau Central nervous system disease associated with Langerhans' cell histiocytosis Am J Pediatr Hematol Oncol 15 1993 245 254
85. N. Grois Y. Tsunematsu A.J. Barkovich Central nervous system disease in Langerhans cell histiocytosis Br J Cancer 23 suppl 1994 24 28
86. E.C. Guinan J.G. Gribben V.A. Boussiotis Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity Blood 84 1994 3261 3282
87. P.J. Hadfield M.A. Birchall D.M. Albert Otitis externa in Langerhans' cell histiocytosis—the successful use of topical nitrogen mustard Int J Pediatr Otorhinolaryngol 30 1994 143 149
88. D.T. Hagerty Intercellular adhesion molecule-1 is necessary but not sufficient to activate CD4 + T cells. Discovery of a novel costimulator on kidney tubule cells J Immunol 156 1996 3652 3659
89. N. Hagimoto K. Kuwano Y. Nomoto Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice Am J Respir Cell Mol Biol 16 1997 91 101
90. J. Halton A. Whitton J. Wiernikowski Disseminated Langerhans cell histiocytosis in identical twins unresponsive to recombinant human alpha-interferon and total body irradiation Am J Pediatr Hematol Oncol 14 1992 269 272
91. C. Hammerberg N. Duraiswamy K.D. Cooper Temporal correlation between UV radiation locally-inducible tolerance and the sequential appearance of dermal, then epidermal, class II MHC+CD11b+ monocytic/macrophagic cells J Invest Dermatol 107 1996 755 763
92. D.T. Harris In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood Bone Marrow Transplant 15 1995 17 23
93. K.E. Hellstrom L. Chen I. Hellstrom Costimulation of T-cell–mediated tumor immunity Cancer Chemother Pharmacol 38 1996 S40 S41
94. J.A. Hickman C.S. Potten A.J. Merritt Apoptosis and cancer chemotherapy Philosophical Transactions of the Royal Society of London–Series B: Biological Sciences 345 1994 319 325
95. M. Hirose K. Ishimoto T. Ninomiya Treatment of patients with Langerhans cell histiocytosis with vindesine J Pediatr Hematol Oncol 18 1996 421 422
96. M. Hirose S. Saito T. Yoshimoto Interleukin-2 therapy of Langerhans cell histiocytosis Acta Paediatrica 84 1995 1204 1206
97. W.G. Hocking M. Swanson Multifocal eosinophilic granuloma. Response of a patient to etoposide Cancer 58 1986 840 842
98. G.W. Hunninghake A.R. Kalica Approaches to the treatment of pulmonary fibrosis Am J Respir Crit Care Med 151 1995 915 918
99. E. Ishii A. Matsuzaki J. Okamura Treatment of Langerhans cell histiocytosis in children with etoposide Am J Clin Oncol 15 1992 515 517
100. K. Iwatsuki M. Tsugiki N. Yoshizawa The effect of phototherapies on cutaneous lesions of histiocytosis-X in the elderly Cancer 57 1986 1931
101. A.M. Jakobson A. Kreuger H. Hagberg Treatment of Langerhans cell histiocytosis with alpha-interferon Lancet 2 1987 1520
102. C.S. Johnson M.J. Chang S.M. Thurlow Immunotherapeutic approaches to leukemia: The use of the Friend virus–induced erythroleukemia model system Cancer Res 50 1990 5682S 5686S
103. G. Kannourakis A. Abbas The role of cytokines in the pathogenesis of Langerhans cell histiocytosis Br J Cancer 23 suppl 1994 S37 S40
104. S.B. Kaye Clinical drug resistance: The role of factors other than P-glycoprotein Am J Med 99 1995 40S 44S
105. C.L. Kelley The role of interferons in the treatment of multiple sclerosis J Neurosci Nurs 28 1996 114 120
106. K.M. Kelly P.C. Beverley A.C. Chu Successful in vivo immunolocalization of Langerhans cell histiocytosis with use of a monoclonal antibody, NA1/34 J Pediatr 125 1994 717 722
107. T. Kitajima K. Ariizumi P.R. Bergstresser Ultraviolet B radiation sensitizes a murine epidermal dendritic cell line (XS52) to undergo apoptosis upon antigen presentation to T cells J Immunol 157 1996 3312 3316
108. T. Kitajima K. Ariizumi M. Mohamadazadeh T cell–dependent secretion of IL-1 beta by a dendritic cell line (XS52) derived from murine epidermis J Immunol 155 1995 3794 3800
109. T.A. Knox M.M. Kaplan A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis Gastroenterology 106 1994 494 499
110. S.A. Kocoshis A. Tzakis S. Todo Pediatric liver transplantation. History, recent innovations, and outlook for the future Clin Pediatr 32 1993 386 392
111. D.M. Komp Historical perspectives of Langerhans cell histiocytosis Hematol Oncol Clin North Am 1 1987 9 21
112. D.M. Komp R. Trueworthy E. Hvizdala Prednisolone, methotrexate, and 6-mercaptopurine in the treatment of histiocytosis X Cancer Treat Rep 63 1979 2125 2126
113. S.M. Kornblau V. Gandhi H.M. Andreeff Clinical and laboratory studies of 2-chlorodeoxyadenosine +/− cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults Leukemia 10 1996 1563 1569
114. S.L. Kunkel N.W. Lukacs R.M. Strieter Th1 and Th2 responses regulate experimental lung granuloma development Sarcoidosis Vasculitis and Diffuse Lung Diseases 13 1996 120 128
115. J. Kurtzberg Umbilical cord blood: A novel alternative source of hematopoietic stem cells for bone marrow transplantation [editorial] J Hematother 5 1996 95 96
116. K. Kyokane T. Ichihara M. Horisawa Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid Hepatogastroenterology 41 1994 449 452
117. S. Ladisch H. Gadner Treatment of Langerhans cell histiocytosis—evolution and current approaches Br J Cancer 23 suppl 1994 S41 S46
118. S. Ladisch H. Gadner M. Arico LCH-I: A randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society Med Pediatr Oncol 23 1994 107 110
119. S. Ladisch E.S. Jaffe The histiocytoses P.A. Pizzo D.G. Poplack Principles and Practice of Pediatric Oncology. 1993 JB Lippincott Philadelphia 617 633
120. M.E. Lahey Histiocytosis X—comparison of three treatment regimens J Pediatr 87 1975 179 183
121. A. Lanzavecchia Mechanisms of antigen uptake for presentation Curr Opin Immunol 8 1996 348 354
122. R.A. Larson R. Mick R.T. Spielberger Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies J Clin Oncol 14 1996 188 195
123. F. Lauria 2-Chlorodeoxyadenosine, a “novel” agent in the treatment of both lymphoid and myeloid malignancies Haematologica 77 1992 443 445
124. D.J. Lenschow G.H. Su L.A. Zuckerman Expression and functional significance of an additional ligand for CTLA-4 Proc Natl Acad Sci USA 90 1993 11054 11058
125. P.H. Lieberman C.R. Jones R.M. Steinman Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years Am J Surg Pathol 20 1996 519 552
126. K.D. Lindor R.A. Jorgensen M.L. Anderson Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: A pilot study Am J Gastroenterol 91 1996 511 515
127. P.S. Linsley P.M. Wallace J. Johnson Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule Science 257 1992 792 795
128. J.M. Lipton The pathogenesis, diagnosis and treatment of histiocytosis syndromes Pediatr Dermatol 1 1983 112 120
129. F. Locatelli A. Pession P. Comoli Role of allogeneic bone marrow transplantation from an HLA-identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukaemia Br J Haematol 92 1996 49 54
130. R. Loire J. Brune Severe late stage lesions of pulmonary histiocytosis X. Report of 3 transplantations Revue des Maladies Respiratoires 10 1993 223 228
131. L. Lu R.N. Shen H.E. Broxmeyer Stem cells from bone marrow, umbilical cord blood and peripheral blood for clinical application: Current status and future application Crit Rev Oncol Hematol 22 1996 61 78
132. E.A. Lukina V.P. Kuznetsov D.L. Beliaev The treatment of histiocytosis X (Langerhans-cell histiocytosis) with alpha-interferon preparations Terapevticheskii Arkhiv 65 1993 67 70
133. H. Mahmoud O. Gaber W. Wang Successful orthotopic liver transplantation in a child with Langerhans cell histiocytosis Transplantation 51 1991 278 280
134. H.H. Mahmoud W.C. Wang S.B. Murphy Cyclosporine therapy for advanced Langerhans cell histiocytosis Blood 77 1991 721 725
135. D.W. Mapel J.M. Samet D.B. Coultas Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future Chest 110 1996 1058 1067
136. T.W. Marcy H.Y. Reynolds Pulmonary histiocytosis-X Lung 163 1985 129 150
137. P.M. Markus X. Cai W. Ming Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506 Transplantation 52 1991 590 594
138. G. Marland A.B. Bakker G.J. Adema Dendritic cells in immune response induction Stem Cells 14 1996 501 507
139. R. Martin H. McFarland Experimental immunotherapies for multiple sclerosis Springer Semin Immunopathol 18 1996 1 24
140. Y. Matsushima T. Baba Resolution of cutaneous lesions of histiocytosis X by intralesional injections of interferon beta Int J Dermatol 30 1991 373 374
141. S.C. Mayou A.C. Chu D.D. Munro Langerhans-cell histiocytosis—excellent response to etoposide Clin Exp Dermatol 16 1991 292 294
142. G.B. McCowage D.P. Frush J. Kurtzberg Successful treatment of two children with Langerhans' cell histiocytosis with 2′-deoxycoformycin J Pediatr Hematol Oncol 18 1996 154 158
143. T.W. McLean J. Pritchard Langerhans cell histiocytosis and hypercalcemia: Clinical response to indomethacin J Pediatr Hematol Oncol 18 1996 318 320
144. H.V. Melendez A. Dhawan G. Mieli-Vergani Liver transplantation for Langerhans' cell histiocytosis—a case report and literature review Transplantation 62 1996 1167 1171
145. P.A. Merkel E.N. Letourneau R.P. Polisson Investigational agents for rheumatoid arthritis Rheum Dis Clin North Am 21 1995 779 796
146. L. Meunier Y. Marck C. Ribeyre Adult cutaneous Langerhans cell histiocytosis: Remission with thalidomide treatment [letter] Br J Dermatol 132 1995 168
147. D.R. Milich P.S. Linsley J.L. Hughes Soluble CTLA-4 can suppress autoantibody production and elicit long term unresponsiveness in a novel transgenic model J Immunol 153 1994 429 435
148. K.J. Minehan M.G. Chen D. Zimmerman Radiation therapy for diabetes insipidus caused by Langerhans cell histiocytosis Int J Radiat Oncol Biol Phys 23 1992 519 524
149. L. Misery B. Larbre S. Lyonnet Remission of Langerhans cell histiocytosis with thalidomide treatment [letter] Clin Exp Dermatol 18 1993 487
150. A. Montoya K. Mawulawde J. Houck Survival and functional outcome after single and bilateral lung transplantation. Loyola Lung Transplant Team Surgery 116 1994 712 718
151. G. Morgan Myeloablative therapy and bone marrow transplantation for Langerhans' cell histiocytosis Br J Cancer 23 suppl 1994 S52 S53
152. P.J. Morris Cyclosporine, FK-506 and other drugs in organ transplantation Curr Opin Immunol 3 1991 748 751
153. J. Morton K. Taylor I. Bunce High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group Br J Haematol 95 1996 110 115
154. A. Nademanee G.M. Schmidt P. Parker The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone Blood 86 1995 1228 1234
155. S. Nagata Apoptosis: Telling cells their time is up Curr Biol 6 1996 1241 1243
156. S. Nagata Fas-mediated apoptosis Adv Exp Med Biol 406 1996 119 124
157. J.R. Nethercott A.H. Murray W. Medwidsky Histiocytosis X in two adults. Treatment with topical mechlorethamine Arch Dermatol 119 1983 157 161
158. A.W. Nienhuis Gene transfer into hematopoietic stem cells Blood Cells 20 1994 141 147
159. S.R. Nondahl J.L. Finlay P.M. Farrell A case report and literature review of “primary” pulmonary histiocytosis X of childhood Med Pediatr Oncol 14 1986 57 62
160. K. Nooter G. Stoter Molecular mechanisms of multidrug resistance in cancer chemotherapy Pathology, Research & Practice 192 1996 768 780
161. M.E. Osband Immunotherapy of histiocytosis-X Hematol Oncol Clin North Am 1 1987 131 146
162. Osband M.E. Lipton J.M. Lavin P. Histiocytosis-X N Engl J Med 304 1981 146 153
163. B.A. Osborne Apoptosis and the maintenance of homoeostasis in the immune system Curr Opin Immunol 8 1996 245 254
164. O. Ostraat Z. Qi G. Gannedahl Moderate additive immunosuppressive effect of thalidomide combined with cyclosporin A in rat cardiac transplantation Transplant Immunol 4 1996 241 246
165. O. Ostraat K. Riesbeck Z. Qi Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro Transplant Immunol 4 1996 117 125
166. P.M. Parker N. Chao A. Nademanee Thalidomide as salvage therapy for chronic graft-versus-host disease Blood 86 1995 3604 3609
167. S.G. Peters J.C. McDougall W.W. Douglas Colchicine in the treatment of pulmonary fibrosis Chest 103 1993 101 104
168. A.J. Petersen R.D. Brown J. Gibson Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro Eur J Haematol 56 1996 213 220
169. P.F. Piguet C. Vesin Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice Eur Respir J 7 1994 515 518
170. P.F. Piguet C. Vesin G.E. Grau Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica Cytokine 5 1993 57 61
171. L.D. Piro D.J. Ellison A. Saven The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia Leuk Lymphoma 14 1994 121 125
172. J.M. Prieto R. Saez E. Carreras Physical and psychosocial functioning of 117 survivors of bone marrow transplantation Bone Marrow Transplant 17 1996 1133 1142
173. D. Przepiorka C. Ippoliti I. Khouri Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation Blood 88 1996 4383 4389
174. N.K. Ramsay S. Davies J. Wagner Bone marrow transplantation. New strategies for treating malignant disease Minnesota Medicine 79 1996 23 28
175. E.B. Rand P.F. Whitington Successful orthotopic liver transplantation in two patients with liver failure due to sclerosing cholangitis with Langerhans cell histiocytosis J Pediatr Gastroenterol Nutr 15 1992 202 207
176. J.C. Reed Bcl-2: Prevention of apoptosis as a mechanism of drug resistance Hematol Oncol Clin North Am 9 1995 451 473
177. R.H. Reist R.D. Dey J.P. Durham Inhibition of proliferative activity of pulmonary fibroblasts by tetrandrine Toxicol Appl Pharmacol 122 1993 70 76
178. O. Ringden L. Ahstrom B. Lonnqvist Allogeneic bone marrow transplantation in a patient with chemotherapy-resistant progressive histiocytosis X N Engl J Med 316 1987 733
179. K.E. Rosenzweig R.J. Arceci N.J. Tarbell Diabetes insipidus secondary to Langerhans' cell histiocytosis: Is radiation therapy indicated? Med Pediatr Oncol 29 1997 36 40
180. G. Ruberti I. Cascino G. Papoff Fas splicing variants and their effect on apoptosis Adv Exp Med Biol 406 1996 125 134
181. P. Rubin C.J. Johnston J.P. Williams A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis Int J Radiat Oncol Biol Phys 33 1995 99 109
182. H. Sakai M. Ibe H. Takahashi Satisfactory remission achieved by PUVA therapy in Langerhans cell histiocytosis in an elderly patient J Dermatol 23 1996 42 46
183. W.J. Sandborn R.H. Wiesner W.J. Tremaine Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin Gut 34 1993 242 246
184. Y. Sato Y. Ikeda E. Ito Histiocytosis X: Successful treatment with recombinant interferon-alpha A Acta Paediatrica Japonica 32 1990 151 154
185. A. Saven M.L. Figueroa L.D. Piro 2-Chlorodeoxyadenosine to treat refractory histiocytosis X N Engl J Med 329 1993 734 735
186. Seymour J.F. Talpaz M. Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up Leukemia 11 1997 42 47
187. M.P. Sheehan D.J. Atherton V. Broadbent Topical nitrogen mustard: An effective treatment for cutaneous Langerhans cell histiocytosis J Pediatr 119 1991 317
188. M. Shito G. Wakabayashi M. Ueda Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat Transplantation 63 1997 143 148
189. M.R. Shurin Dendritic cells presenting tumor antigen Cancer Immunol Immunother 43 1996 158 164
190. J.F. Sommerauer P. Atkison W. Andrews Liver transplantation for Langerhans' cell histiocytosis and immunomodulation of disease pre- and posttransplant Transplant Proc 26 1994 178 179
191. J.M. Soos H.M. Johnson Type I interferon inhibition of superantigen stimulation: Implications for treatment of superantigen-associated disease Journal of Interferon & Cytokine Research 15 1995 39 45
192. T.L. Spray G.B. Mallory C.B. Canter Pediatric lung transplantation. Indications, techniques, and early results J Thorac Cardiovasc Surg 107 1994 990 999
193. S. Stewart K. McNeil S.A. Nashef Audit of referral and explant diagnoses in lung transplantation: A pathologic study of lungs removed for parenchymal disease J Heart Lung Transplant 14 1995 1173 1186
194. A.C. Stieber C. Sever T.E. Starzl Liver transplantation in patients with Langerhans' cell histiocytosis Transplantation 50 1990 338 340
195. M. Stoll M. Freund H. Schmid Allogeneic bone marrow transplantation for Langerhans' cell histiocytosis Cancer 66 1990 284
196. I.A. Tabbara Allogeneic bone marrow transplantation South Med J 89 1996 857 868
197. P. Tan C. Anasetti J.A. Hansen Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1 J Exp Med 177 1993 165 173
198. L. Thomas B. Ducros T. Secchi Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review Arch Dermatol 129 1993 1261 1264
199. E. Tsele D.M. Thomas A.C. Chu Treatment of adult Langerhans cell histiocytosis with etoposide J Am Acad Dermatol 27 1992 61
200. E.N. Unemori L.B. Pickford A.L. Salles Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo J Clin Invest 98 1996 2739 2745
201. J.R. Usher D. Henderson Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs IMA Journal of Mathematics Applied in Medicine & Biology 13 1996 99 126
202. K. Uthoff K.J. Zehr P.B. Gaudin Thalidomide as replacement for steroids in immunosuppression after lung transplantation Ann Thorac Surg 59 1995 277 282
203. M. van Krugten N.A. Cobben R.J. Lamers Serum LDH: A marker of disease activity and its response to therapy in idiopathic pulmonary fibrosis Neth J Med 48 1996 220 223
204. D.H. Van Thiel P. Carroll K. Abu-Elmagd Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: Results of an open-label preliminary trial Am J Gastroenterol 90 1995 455 459
205. G. Varadi U. Elchalal C. Brautbar Human umbilical cord blood for hematopoietic progenitor cells transplantation Leuk Lymphoma 20 1995 51 58
206. M.B. Viana B.M. Oliveira C.M. Silva Etoposide in the treatment of six children with Langerhans cell histiocytosis (histiocytosis X) Med Pediatr Oncol 19 1991 289 294
207. J.E. Wagner Umbilical cord blood transplantation: Overview of the clinical experience Blood Cells 20 1994 227 233
208. J.E. Wagner N.A. Kernan M. Steinbuch Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease Lancet 346 1995 214 219
209. A.S. Wayne C.T.C. Tan R.J. Arceci 2-Chlorodeoxyadenosine (2CDA) for disorders of mono-histiocytic lineage Blood 84 1994 57a
210. C.L. Willman Detection of clonal histiocytes in Langerhans cell histiocytosis: Biology and clinical significance Br J Cancer 23 suppl 1994 S29 S33
211. C.L. Willman L. Busque B.B. Griffith Langerhans-cell histiocytosis (histiocytosis X)—a clonal proliferative disease N Engl J Med 331 1994 154 160
212. J. Winiarski O. Ringden M. Remberger Bone marrow transplantation in children using unrelated donors at Huddinge Hospital Acta Paediatrica 85 1996 327 335
213. J.D. Wirtschafter M. Nesbit P. Anderson Intralesional methylprednisolone for Langerhans' cell histiocytosis of the orbit and cranium J Pediatr Ophthalmol Strabismus 24 1987 194 197
214. R.B. Womer K.R. Anunciato M. Chehrenama Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis Med Pediatr Oncol 25 1995 70 73
215. M.N. Woodroofe Cytokine production in the central nervous system Neurology 45 1995 S6 S10
216. K. Wosikowski J.T. Regis R.W. Robey Normal p53 status and function despite the development of drug resistance in human breast cancer cells Cell Growth Differ 6 1995 1395 1403
217. M. Yeatman K. McNeil J.A. Smith Lung transplantation in patients with systemic diseases: An eleven-year experience at Papworth Hospital J Heart Lung Transplant 15 1996 144 149
218. R.C. Yu A. Chu L. Buluwela Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis Lancet 343 1994 767 768
219. P. Zandi Y. Panis D. Debray Pediatric liver transplantation for Langerhans' cell histiocytosis Hepatology 21 1995 129 133
220. H.Y. Zhang M. Gharaee-Kermani S.H. Phan Regulation of lung fibroblast alpha-smooth muscle actin expression, contractile phenotype, and apoptosis by IL-1beta J Immunol 158 1997 1392 1399
221. K. Zhang K.C. Flanders S.H. Phan Cellular localization of transforming growth factor-beta expression in bleomycin-induced pulmonary fibrosis Am J Pathol 147 1995 352 361
222. K. Zhang M. Gharaee-Kermani B. McGarry TNF-alpha–mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis J Immunol 158 1997 954 959
223. P.L. Zinzani P. Tosi G. Visani Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells Am J Hematol 47 1994 301 306